Tirzepatida
GIP/GLP-1 co-agonist (dual incretin)
Dual incretin agonist with marked metabolic and weight effect.
Back to technical sheets- Class
- GIP/GLP-1 co-agonist (dual incretin)
- Also known as
- Marketed as tirzepatide (e.g. Mounjaro®, Zepbound®)
Mechanism of action
Dual agonist of the GIP and GLP-1 receptors. Combined activation of both incretin pathways improves glycemic control and satiety, with additive effects on weight loss compared with GLP-1 agonism alone.
Evidence
Solid clinical evidence: regulatory approval and trial programs (SURPASS in diabetes, SURMOUNT in obesity).
Studied uses
- Type 2 diabetes mellitus
- Obesity and overweight with comorbidity
Safety considerations
- Frequent gastrointestinal effects
- Same thyroid warnings (medullary carcinoma / MEN2)
- Do not use in pregnancy; adjust with other glucose-lowering agents
Batch quality data
We publish these figures because they are the ones the program itself teaches you to ask for.
- Purity
- ≥ 99 % (HPLC)
- Net content
- 80 %
- Batch
- TIR-2601
- Presentation
- Polvo liofilizado en vial sellado
Net content is the fraction of the vial’s weight that is actually peptide, after discounting water, salts and excipients. It is the figure to calculate with, not the label weight.
Sample prices and batch data while the real ones are loaded.
Educational reference sheet. It is not a recommendation to use, a clinical indication or a protocol. Many of these compounds are marketed for research use only and are not approved for human use. Always cross-check with the primary literature and the regulation in your country.